Together with our previous study on VKH disease, these results seem to suggest that CsA may exerts its therapeutic effect on BD possibly through inhibiting IL-17 and IFN-γ and that it may be universally used for the treatment of diseases mediated by IL-17 as well as IFN-γ. This evidence concerns the gene IFNG and Behcet disease.